SR9009 10 10 mg Deus Medical
Discover the Power of SR9009 10 10 mg Deus Medical
Introducing SR9009 10 10 mg Deus Medical, a cutting-edge compound renowned for its ability to enhance athletic performance and support weight management. This product is a member of the SARM (Selective Androgen Receptor Modulator) family known as Stenabolic, which focuses on activating the Rev-ErbA receptor. By doing so, it plays a pivotal role in increasing mitochondrial activity within muscle cells, leading to improved endurance and reduced fat storage. With its precise formulation and measurable benefits, SR9009 10 10 mg Deus Medical is designed for individuals seeking to optimise their physical capabilities and achieve their fitness goals.
Unleashing the Advantages of Stenabolic
When considering a supplement like SR9009 10 10 mg, it’s essential to understand the distinct advantages it offers users. This compound not only aids those keen on improving their physical performance but also provides a range of beneficial effects that can enhance overall well-being. By integrating SR9009 into your regimen, you might experience:
- Increased endurance for longer workout sessions.
- Reduced fat accumulation, leading to a leaner physique.
- Enhanced wakefulness, ensuring you remain energised throughout the day.
- Minimal water retention, supporting a more defined look.
These benefits make SR9009 10 10 mg Deus Medical a valuable addition to your fitness routine, whether you are a competitive athlete or simply looking to improve your overall health and fitness.
Long-Term Benefits and Practical Uses of SR9009 10 10 mg Deus Medical
The long-term implications of using SR9009 10 10 mg Deus Medical are equally impressive. As a synthetic drug, its primary action is linked to mitochondrial enhancement and fat metabolism. One of the noteworthy features of this product is its relatively short half-life of 4-5 hours, which allows for flexible dosing schedules to suit individual needs. Regular use can contribute to sustained enhancements in physical performance and metabolic health, making it an attractive option for anyone dedicated to their fitness journey.
Moreover, its minimal impact on blood pressure and lack of significant water retention sets it apart from many other performance-enhancing substances, making SR9009 not only effective but also safer for long-term use. While data on its hepatotoxicity are limited, the absence of prominent side effects associated with its use adds to its appeal for fitness enthusiasts. Store the product at room temperature away from moisture and light to maintain its potency, ensuring you receive the maximum benefits each time.
| Active substance | SARMs |
|---|---|
| Release form | Pack (25 Pills) |
| Water Retention | No significant water retention |
| Hepatotoxicity | Not enough data to determine |
| Lab Test | Specific tests for detection in blood or urine not widely detailed |
| Also known as | SR9009, Stenabolic |
| Blood pressure | No significant impact reported |
| Trade name | Not available under any trade name as it is not commercially marketed |
| Storage conditions | Store at room temperature away from moisture and light |
| Chemical name | Ethyl 3-[[(4-chlorobenzyl)((5-nitrothiophen-2-yl)methyl)amino]methyl]pyrrolidine-1-carboxylate |
| Formula | C20H24ClN3O4S |
| Substance class | Synthetic drug, Rev-ErbA ligand |
| Main action | Activates Rev-ErbA which increases mitochondrial count in muscle, decreases fat storage |
| Half-life | Approximately 4-5 hours |
| Dosage (medical) | Not clinically approved for medical use |
| Dosage (sports) | Typically 10-40 mg per day |
| Effects | Increased endurance, reduced fat mass, increased wakefulness |
| Side effects | Potential alterations in circadian rhythms, limited data on long-term effects |
| Use in sports | Used as a performance-enhancing drug, not approved by WADA |
| Active ingredient, mg | 10 |
| 1 Pill, mg | 10 |
| Manufacturer | DEUS MEDICAL |
| Packing | Package (50 Pills) |
| 5 |
|
0 |
| 4 |
|
0 |
| 3 |
|
0 |
| 2 |
|
0 |
| 1 |
|
0 |


Reviews
There are no reviews yet.